Liquid Chromatography/Mass Spectrometry (LC/MS)-Based Glycoproteomics Technologies for Cancer Biomarker Discovery

Clinical Proteomics

Toshiaki Isobe²  Hiroyuki Kaji¹ 

[1] Glycoproteomics Team, Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, JapanDepartment of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, JapanGlycoproteomics Team, Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, JapanGlycoproteomics Team, Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, JapanDepartment of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, JapanDepartment of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, JapanGlycoproteomics Team, Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, JapanDepartment of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, Japan;Department of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, JapanCREST, Japan Science and Technology Agency, Kawaguchi, JapanDepartment of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, JapanDepartment of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, JapanCREST, Japan Science and Technology Agency, Kawaguchi, JapanCREST, Japan Science and Technology Agency, Kawaguchi, JapanDepartment of Chemistry, Graduate School of Science and Engineering, Tokyo Metropolitan University, Hachioji, JapanCREST, Japan Science and Technology Agency, Kawaguchi, Japan

关键词: Liquid chromatography;    Mass spectrometry;    Proteome;    Glycoproteins;    Glycoproteomics;    Biomarker;    Cancer;   

DOI  :  10.1007/s12014-008-9004-1

来源: Humana Press Inc

【 摘 要 】

Abstract

Introduction

Biomarker discovery is a major objective of clinical proteomics; molecular biomarkers allow for detection of early-stage human diseases, especially cancer, and for monitoring their progression and/or regression after treatment. Biomarkers also help to elucidate the pathology of disease and its diagnosis, drug discovery, and toxicology. Glycans are ideal candidates for biomarkers because (1) glycoconjugates are localized on the cell surface and in the secretions such as plasma, (2) their structures are frequently and drastically changed during normal and aberrant cell differentiation, and (3) different cell types express different glycan signatures. Certain serodiagnostic glycoconjugate markers, such as carcinoembryonic antigen (CEA), are currently available; however, comprehensive glycome analysis has yet to be performed, mainly because of the difficulties of isolating and structurally analyzing complex glycans. Large-scale glycoprotein analysis, termed glycoproteomics, has the potential to effectively trace cellular glycoproteins and therefore to search for new serodiagnostic biomarkers.

Conclusions

In this review, we describe current mass spectrometry-based glycoproteomics technologies. Quantitative “shotgun” proteomics analyses of glycopeptides captured from complex biological mixtures such as plasma, coupled with advanced glycome technologies, enhance our knowledge of protein glycosylation and facilitate discovery of new biomarkers for human diseases.

【 授权许可】

Unknown